SYS6002 (CRB-701) Phase 1 Results at ASCO GU 2024

Corbus Pharmaceuticals, a company focused on precision oncology, has announced the release of the abstract for the Phase 1 clinical trial of SYS6002 (CRB-701), a novel antibody-drug conjugate (ADC). The study's findings, which will be updated to include data from December 2023, are set to be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The trial is being conducted in partnership with CSPC Pharmaceutical Group in China and is designed to evaluate the safety and efficacy of the drug in patients with advanced solid tumors.

SYS6002 (CRB-701) is an innovative treatment that targets the nectin-4 protein, which is found in various types of cancer. The drug is administered on a quarterly basis with the aim of reducing plasma concentrations of free-MMAE, a component known to cause toxic side effects when present in high levels. The study is currently assessing six different dosage levels and utilizes a Bayesian Optimal Interval design to accelerate the dosage titration process.

The upcoming presentation at ASCO GU will feature an expanded dataset that includes information on the drug's safety, tolerability, anti-tumor activity, pharmacokinetics, and the expression levels of nectin-4 in patients with metastatic urothelial cancer, cervical cancer, triple-negative breast cancer, and colorectal cancer. The poster presentation is scheduled for January 26th.

Corbus Pharmaceuticals is also exploring the potential of SYS6002 (CRB-701) as both a standalone treatment and in combination with other therapies. The company plans to continue its development efforts in China, the U.S., and Europe.

CRB-701 (SYS6002) is a next-generation ADC that incorporates a cleavable linker and a uniform drug-to-antibody ratio, using monomethyl auristatin E (MMAE) as its payload. The drug targets the nectin-4 antigen, which has been clinically validated in the treatment of urothelial cancer. PADCEV®, an ADC that also targets nectin-4, has been approved for late-stage metastatic urothelial cancer and has recently received an expanded label for use in combination with KEYTRUDA® for patients with locally advanced or metastatic urothelial carcinoma.

Corbus Pharmaceuticals is dedicated to advancing scientific approaches to address well-understood biological pathways in oncology. The company's pipeline includes CRB-701, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 inverse agonist for obesity treatment. Headquartered in Norwood, Massachusetts, Corbus is committed to developing innovative treatments for serious illnesses.

The company's press release highlights the potential of SYS6002 (CRB-701) as a significant advancement in cancer treatment. The Phase 1 study's abstract and the upcoming presentation at ASCO GU are expected to provide valuable insights into the drug's effectiveness and safety profile, offering hope for patients with advanced solid tumors who have exhausted standard treatment options.